Intravitreal sirolimus for persistent, exudative age-related macular degeneration: a Pilot Study

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
2056-9920
Extent
Online-Ressource
Language
Englisch
Notes
online resource.

Bibliographic citation
Intravitreal sirolimus for persistent, exudative age-related macular degeneration: a Pilot Study ; volume:7 ; number:1 ; day:16 ; month:2 ; year:2021 ; pages:1-10 ; date:12.2021
International Journal of Retina and Vitreous ; 7, Heft 1 (16.2.2021), 1-10, 12.2021

Creator
Minturn, Robert J.
Bracha, Peter
Klein, Margaret J.
Chhablani, Jay
Harless, Ashley M.
Maturi, Raj K.
Contributor
SpringerLink (Online service)

DOI
10.1186/s40942-021-00281-0
URN
urn:nbn:de:101:1-2021040520565570180901
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
14.08.2025, 10:46 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Minturn, Robert J.
  • Bracha, Peter
  • Klein, Margaret J.
  • Chhablani, Jay
  • Harless, Ashley M.
  • Maturi, Raj K.
  • SpringerLink (Online service)

Other Objects (12)

Macular Hole Formation Following Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration

Macular Hole Formation Following Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration

Intravitreal sirolimus with adjunct aflibercept versus aflibercept monotherapy for persistent, exudative age-related macular degeneration: a pilot study

Intravitreal sirolimus with adjunct aflibercept versus aflibercept monotherapy for persistent, exudative age-related macular degeneration: a pilot study

Age-related macular degeneration

Aufsatzsammlung

Age-related macular degeneration

Mortality in patients treated with intravitreal bevacizumab for age-related macular degeneration

Mortality in patients treated with intravitreal bevacizumab for age-related macular degeneration

Intravitreal Brolucizumab for Neovascular Age-Related Macular Degeneration in a Vitrectomized Eye

Intravitreal Brolucizumab for Neovascular Age-Related Macular Degeneration in a Vitrectomized Eye

Macular Hole Surgery in the Case of Wet Age-Related Macular Degeneration Treated with Intravitreal Aflibercept

Macular Hole Surgery in the Case of Wet Age-Related Macular Degeneration Treated with Intravitreal Aflibercept

Unexpected Vision Loss following Six Intravitreal Injections for Neovascular Age-Related Macular Degeneration

Unexpected Vision Loss following Six Intravitreal Injections for Neovascular Age-Related Macular Degeneration

Epiretinal membrane appearance or progression after intravitreal injection in age-related macular degeneration

Epiretinal membrane appearance or progression after intravitreal injection in age-related macular degeneration

Retinal vasculitis after intravitreal aflibercept 8 mg for neovascular age-related macular degeneration

Retinal vasculitis after intravitreal aflibercept 8 mg for neovascular age-related macular degeneration

Intravitreal treatment in patients with exudative age-related macular degeneration and visual acuity ≤ 0.05

Intravitreal treatment in patients with exudative age-related macular degeneration and visual acuity ≤ 0.05

Intravitreal treatment in patients with exudative age-related macular degeneration and visual acuity ≤ 0.05

Intravitreal treatment in patients with exudative age-related macular degeneration and visual acuity ≤ 0.05

Peripapillary choroidal thickness after intravitreal ranibizumab injections in eyes with neovascular age-related macular degeneration

Peripapillary choroidal thickness after intravitreal ranibizumab injections in eyes with neovascular age-related macular degeneration

Related objects